• Product NameHHV8 ORF50 Antibody HRP Conjugated
• Host SpeciesRabbit
• ClonalityPolyclonal
• IsotypeIgG
• PurificationPurified by Protein A.
• ApplicationsWB IHC-P IHC-F
• Species Reactivityherpesvirus8typeP
• Crossing ReactivityHHV8
• Immunogen DescriptionKLH conjugated synthetic peptide aa 500-550 691 derived from human HHV8 ORF50
• ConjugatesHRP
• Excitation EmissionN A
• Target NameHHV8 ORF50
• Alternative Names    HHV8 ORF50; HHV 8; Human Herpes Virus 8; Human herpesvirus 8; Kaposi's sarcoma associated herpes virus; Kaposi's sarcoma associated herpesvirus; KSHV.
• Concentration 1mg ml
• Formulation 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
• Storage Shipped at 4˚C. Store at -20˚C for one year. Avoid repeated freeze/thaw cycles.

• WB=1:500-2000 IHC-P=1:50-200 IHC-F=1:50-200

HHV8 has been found to be associated with three different diseases observed in AIDS patients; kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting